Providers and hospitals often see the insurance company as their end customer, not the patient, which is why the consumer experience is not optimized.

As many as 85-90% of drugs that enter Phase II human trials fail, and the cost of these failures is passed on to the few successful drugs.

Companies are already developing AI bots that can call multiple doctor's offices to find and schedule the best appointment for you.

We are likely only three to five years away from AI therapists that are so advanced you may not be able to tell if they are human.

In the next 30 years, it's predicted that 90% of all healthcare will be delivered directly through your phone.

While AI is more expensive than traditional software, it is significantly cheaper than human services, making it ideal for disrupting the service-heavy healthcare industry.

Biology is shifting from an artisanal craft into a systematic engineering discipline, allowing for programmable approaches to health and medicine.

When an AI is trained on millions of conversations with empathetic nurses, the AI itself can learn and exhibit empathy.

Only one of the hundred biggest software companies in the world is a healthcare company, which highlights the industry's lack of technological penetration.

Unlike the usual fast growth seen with vanity drugs, there is a new, powerful consumer demand for preventative healthcare, signaling a major shift in the market.